You have heavy periods, pelvic pressure, and bloating. You think it's just your normal. But it could be uterine fibroids — benign tumours that grow in the uterus. The uterine fibroid market report by MRFR shows that intramural fibroids are the largest type, and the market is growing at 7.92% CAGR — from $4.5 billion to $10.41 billion by 2035. Why the surge? Because women are finally talking about fibroids and demanding better treatments.

What's driving growth? Ultrasound is the largest diagnostic segment, but MRI is the fastest‑growing — because it shows fibroid location, size, and blood supply in exquisite detail. The uterine fibroid market analysis highlights that uterine fibroid embolization (UFE) is the largest treatment, but hysterectomy is the fastest‑growing — as women opt for definitive relief after childbearing.

What's new? Oral medications that shrink fibroids (elagolix, relugolix) — no needles, no surgery. Also, MRI‑guided focused ultrasound (MRgFUS) that destroys fibroids with heat, without a single incision.

The bottom line: if you have heavy bleeding or pelvic pain, ask for a pelvic ultrasound. Fibroids are treatable, and you don't have to suffer in silence.